Glucocorticoids in nephrology II: indications and dosage
Abstract
Present article describes glucocorticoid prescriptions in nephrology and renal transplantation, the dosages in induction and maintenance treatment phases and discontinuation. Key evidence and landmark trials are referenced, to establish the basis for modern glucocorticoid application in specific kidney disease indications. The glucocorticoid regimens in IgA glomerulonephritis, major primary glomerular diseases with nephrotic syndrome, vasculitides and tubulointerstitial nephritis are described. Various schemes for glucocorticoid dosage in lupus nephritis are given. The evolution of glucocorticoid usage in kidney transplantation is delineated and the modern role of these drugs in renal transplantation is defined. There are attempts to replace glucocorticoids with adrenocorticotrophic hormone in some glomerular diseases. Despite being relatively old drugs and having numerous side effects, glucocorticoids still function as major therapeutic agents for specific immunosuppressive treatment in nephrology.
Downloads
References
Reich HN, Troyanov S, Scholey JW, Cattran DC. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007; 18: 3177–83.
Julian BA, Novak J. IgA nephropathy: an update. Curr Opin Nephrol Hypertens. 2004; 13: 171–9.
Cattran DC, Coppo R, Cook HT, Feehally J, Roberts ISD, Troyanov S, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009; 76: 534–45.
Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014; 86: 828–36.
Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004; 15: 157–63.
Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2009; 53: 26–32.
Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transpl. 2009; 24: 3694–701.
Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999; 353: 883–7.
Kovač D, Aleš Rigler A, Pajek J, Kveder R, Škoberne A, Vizjak A, et al. Treatment of patients with IgA nephropathy - our experience. In: Marn Pernat A, editor. 5th Slovenian Congress of Nephrology with International Participation, final program, invited lectures and book of abstracts. Ljubljana: Slovenian Society of Nephrology; 2012. p. 50–1.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Inter Suppl. 2012; 2: 139–274.
Meyrier A. Management of idiopathic nephrotic syndrome in adults: minimal change disease and focal segmental glomerulosclerosis. In: Molony DA, Craig JC, editors. Evidence-based Nephrology. Oxford: Wiley-Blackwell; 2009. p. 149–57.
Mason PD, Hoyer PF. Minimal change nephrotic syndrome. In: Floege J, Johnson RJ, Feehaly J, editors. Comprehensive Clinical Nephrology. 4th ed. St. Louis: Elsevier Inc.; 2010. p. 218–27.
Nakayama M, Katafuchi R, Yanase T, Ikeda K, Tanaka H, Fujimi S. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis. 2002; 39: 503–12.
Black DA, Rose G, Brewer DB. Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br Med J. 1970; 3: 421–6.
Bose B, Cattran D. Glomerular Diseases: FSGS. Clin J Am Soc Nephrol. 2014; 9: 626–32.
Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999; 56: 2220–6.
Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011; 80: 868–78.
Meyrier AY. Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis? Kidney Int. 2009; 76: 487–91.
Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010; 21: 697–704.
Fervenza FC, Cattran DC. Membranous Nephropathy. In: Molony DA, Craig JC, editors. Evidence-based Nephrology. Oxford: Wiley-Blackwell; 2009. p. 158–69.
Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998; 9: 444–50.
Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney int. 2001; 59: 1484–90.
Aleš Rigler A. Sistemski vaskulitis in ledvice. In: Lindič J, Kovač D, Kveder R,
Malovrh M, Pajek J, Aleš Rigler A, et al., editors. Bolezn. ledvic. 3rd ed. Ljubljana: Slovensko zdravniško društvo - Slovensko nefrološko društvo in Univerzitetni klinični center Ljubljana - Klinični oddelek za nefrologijo, Interna klinika; 2014. p. 253–60.
Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009; 68: 310–7.
Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med. 2005; 143: 621–31.
Sanders J-SF, Huitma MG, Kallenberg CGM, Stegeman C a. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatol. 2006; 45: 724–9.
Hench PS, Kendall EC, Slocumb CH, Polley HF. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med. 1950; 85: 545–666.
Barron KS, Person DA, Brewer EJ, Beale MG, Robson AM. Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. J Pediatr. 1982; 101: 137–41.
Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992; 340: 741–5.
Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20: 1103–12.
Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JHM, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012; 71: 1771–82.
Franchin G, Diamond B. Pulse steroids: how much is enough? Autoimmun Rev. 2006; 5: 111–3.
Parker BJ, Bruce IN. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus. 2007; 16: 387–93.
Sinclair A, Appel G, Dooley M a, Ginzler E, Isenberg D, Jayne D, et al. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus. 2007; 16: 972–80.
Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido Ed EDR, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002; 46: 2121–31.
Ruiz-Irastorza G, Danza A, Perales I, Villar I, Garcia M, Delgado S, et al. Prednisone in lupus nephritis: how much is enough? Autoimmun Rev. 2014; 13: 206–14.
Lindič J, Avguštin N, Aleš Rigler A, Kveder R, Pajek J, Škoberne A, et al. Combined low dose cyclophosphamide i.v. pulse and methylprednisolone therapy is successful in the treatment of lupus nephritis. In: Marn Pernat A, editor. 5th Slovenian Congress of Nephrology with International Participation, final program, invited lectures and book of abstracts. Ljubljana: Slovenian Society of Nephrology; 2012. p. 114.
Bose B, Silverman ED, Bargman JM. Ten Common Mistakes in the Management of Lupus Nephritis. Am J Kidney Dis. 2014; 63: 667–76.
Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transpl. 2004; 19: 8–11.
Michel DM, Kelly CJ. Acute interstitial nephritis. J Am Soc Nephrol. 1998; 9: 506–15.
González E, Gutiérrez E, Galeano C, Chevia C, de Sequera P, Bernis C, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008; 73: 940–6.
Starzl TE, Rosenthal JT, Hakala TR, Iwatsuki S, Shaw BW, Klintmalm GB. Steps in immunosuppression for renal transplantation. Kidney Int Suppl. 1983; 14: S60–5.
Opelz G, Döhler B. Association between steroid dosage and death with a functioning graft after kidney transplantation. Am J Transpl. 2013; 13: 2096–105.
Opelz G, Döhler B, Laux G. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transpl. 2005; 5: 720–8.
Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008; 248: 564–77.
Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation. 2010; 89: 1–14.
Cortazar F, Diaz-Wong R, Roth D, Isakova T. Corticosteroid and calcineurin inhibitor sparing regimens in kidney transplantation. Nephrol Dial Transpl. 2013; 28: 2708–16.
Pascual J, Royuela A, Galeano C, Crespo M, Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transpl. 2012; 27: 825–32.
Pascual J, Galeano C, Royuela A, Zamora J. A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation. 2010; 90: 343–9.
Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff ’09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transpl. 2010; 10: 464–71.
Aleš A. Akutna celična zavrnitev presajene ledvice. In: Arnol M, Kandus A, Bren A, Buturović Ponikvar J, editors. Presaditev ledvic. 1st ed. Ljubljana: Klinični oddelek za nefrologijo Interna klinika, Univerzitetni klinični center Ljubljana; 2009. p. 189–96.
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transpl. 2009;9 Suppl 3: S1–155.
Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation. 2012; 94: 775–83.
Puttarajappa C, Shapiro R, Tan HP. Antibody-mediated rejection in kidney transplantation: a review. J Transpl. 2012; 2012: 193724.
Arneil GC, Wilson HEC. A.C.T.H. in nephrosis. Arch Dis Child. 1953; 28: 372–80.
Berg a L, Nilsson-Ehle P, Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int. 1999; 56: 1534–43.
Ponticelli C, Passerini P, Salvadori M, Manno C, Viola BF, Pasquali S, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis. 2006; 47: 233–40.
Hogan J, Bomback AS, Mehta K, Canetta PA, Rao MK, Appel GB, et al. Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin J Am Soc Nephrol. 2013; 8: 2072–81.
Bomback AS, Canetta PA, Beck LH, Ayalon R, Radhakrishnan J, Appel GB. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am J Nephrol. 2012; 36: 58–67.
Bomback AS, Radhakrishnan J. Treatment of Nephrotic Syndrome with Adrenocorticotropic Hormone (ACTH). Discov Med. 2011; 12: 91–6.
Gong R. The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol. 2012; 8: 122–8.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
